Genomtec S.A. Logo

Genomtec S.A.

Develops mobile platforms for rapid, point-of-care molecular diagnostics.

GMT | WAR

Overview

Corporate Details

ISIN(s):
PLGNMTC00017
LEI:
259400ND13Y44ADMG554
Country:
Poland
Address:
WROCŁAW BIERUTOWSKA 57-59, 51-317 WROCŁAW

Description

Genomtec S.A. is a technology company specializing in the development of mobile platforms for rapid molecular diagnostics. The company's flagship product is Genomtec ID, a portable point-of-care system for genetic testing that combines the amplification and detection of specific DNA and RNA fragments. This technology enables fast and accurate analysis without requiring specialized laboratory infrastructure or personnel. A key application is the CE-IVD certified GenomtecID Respiratory Panel 5-Plex (RP5-PLEX), which detects viruses and bacteria causing respiratory tract infections. The company has also organized its core technologies, the Genomtec ID platform and the OncoSNAAT oncology project, into separate special purpose vehicles to facilitate strategic development and potential M&A processes.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-11 14:27
Otrzymanie od Urzędu Patentowego w Stanach Zjednoczonych decyzji o udzieleniu o…
Polish 2.0 KB
2025-11-28 17:32
zal01_Genomtec_sprawozdanie_III_kw_2025.pdf
Polish 940.2 KB
2025-11-28 17:32
zal02_GENOMTEC_Pozostale_informacje_do_3Q2025.pdf
Polish 958.9 KB
2025-10-15 16:44
Otrzymanie od Europejskiego Urzędu Patentowego decyzji o udzieleniu patentu eur…
Polish 1.4 KB
2025-09-29 18:10
zal04_opinia_RN_do_stanowiska.pdf
Polish 154.5 KB
2025-09-29 18:10
zal05_Stanowisko_Zarzadu_do_zastrzezenia.pdf
Polish 144.6 KB
2025-09-29 18:10
zal03_genomtec_sprawozdanie_zarzadu_ip_2025_vfinal_signed_1.pdf
Polish 1.1 MB
2025-09-29 18:10
zal02_GENOMTEC_PSF_2025_MSR_Raport_z_przegladu_ost.pdf
Polish 420.3 KB
2025-09-29 18:10
zal01_genomtec_sf_06.2025_sig_signed.pdf
Polish 1.6 MB
2025-09-25 17:13
Otrzymanie od Europejskiego Urzędu Patentowego decyzji o udzieleniu patentu eur…
Polish 1.6 KB
2025-09-15 17:12
Otrzymanie od Urzędu Patentowego w Japonii decyzji o udzieleniu ochrony patento…
Polish 2.0 KB
2025-09-15 17:08
Podjęcie przez Zarząd Giełdy Papierów Wartościowych uchwały w sprawie dopuszcze…
Polish 1.0 KB
2025-09-11 17:57
Przyznanie akcji w ramach warunkowego podwyższenia kapitału zakładowegoPrzyznan…
Polish 2.3 KB
2025-08-14 17:28
Przyznanie akcji w ramach warunkowego podwyższenia kapitału zakładowego - Conte…
Polish 2.2 KB
2025-08-01 15:26
Otrzymanie od Urzędu Patentowego w Japonii decyzji o udzieleniu ochrony patento…
Polish 1.7 KB

Automate Your Workflow. Get a real-time feed of all Genomtec S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genomtec S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genomtec S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.